

**IMIDAZONAPHTHYRIDINES, PHARMACEUTICAL COMPOSITION BASED ON THEREOF, METHOD FOR STIMULATING BIOSYNTHESIS OF CYTOKINE AND INTERMEDIATE COMPOUNDS**

**Publication number:** RU2221798 (C2)

**Publication date:** 2004-01-20

**Inventor(s):** LINGSTROM KAJL DZH [US]; GERSTER DZHON F [US] +

**Applicant(s):**

**Classification:**

**- international:** A61K31/4375; A61K31/4439; A61K31/444; A61K31/522; A61P17/00; A61P29/00; A61P31/12; A61P33/00; A61P35/00; A61P37/02; A61P43/00; A61P7/00; C07D401/04; C07D471/04; C07D471/14; C07D471/22; C07D519/00; C07D213/00; C07D233/00; C07D257/00; A61K31/4353; A61K31/4427; A61K31/519; A61P17/00; A61P29/00; A61P31/00; A61P33/00; A61P35/00; A61P37/00; A61P43/00; A61P7/00; C07D401/00; C07D471/00; C07D519/00; C07D213/00; C07D233/00; C07D257/00; (IPC1-7): A61K31/4375; A61K31/4439; A61P31/12; A61P35/00; A61P37/02; C07D213/00; C07D233/00; C07D257/00; C07D401/04; C07D401/04; C07D471/04; C07D471/14; C07D471/14; C07D471/22

**- European:** C07D471/04; C07D471/14

**Application number:** RU20000114496 19981211

**Priority number(s):** US19970069276P 19971211

**Also published as:**

WO9929693 (A1)  
UA67760 (C2)  
TR200001705 (T2)  
SK286304 (B6)  
SK285872 (B6)

more >>

**Abstract of RU 2221798 (C2)**

**FIELD:** organic chemistry, biochemistry, pharmacy. **SUBSTANCE:** invention relates to new imidazonaphthyridines of formulas (I) and (II) wherein A represents =N-CR=CR-CR=, =CR-N= CR-CR=, = CR-CR= N-CR or =CR-CR=CR-N=; B represents NR -C(R)2-C(R)2-C(R)2, C(R)2-NR-C(R)2-C(R)2, -C(R)2 -C(R)2-NR-C(R)2 or C(R)2-C(R)2-C(R)2-NR wherein R is hydrogen atom; R14 is unsubstituted or substituted C1-20-alkyl; C1-20-alkylene-NR3-Q-X-R4 wherein Q represents CO or -SO2-; X is a simple bond, -O- or -NR3; R4 is aryl, heteroaryl, heterocyclyl or C1-20-alkyl or C2-20-alkenyl. Other values of radicals are given in the invention claim. Compounds of formulas (I) and (II) stimulate synthesis of cytokines, such as interferon and tumor necrosis factor and can be used in medicine. Invention relates also to pharmaceutical compositions and intermediate compounds. **EFFECT:** valuable biological and medicinal properties of compounds. 20 cl, 5 tbl, 213 ex

Data supplied from the *espacenet* database — Worldwide